According to the Hindu, the Indian Patent Office has rejected Johnson & Johnson’s attempt to extend a monopoly on a lifesaving TB drug.
In a victory for patients fighting for wider access to crucial anti-tuberculosis drug Bedaquiline, the Indian Patent Office on Thursday rejected U.S. pharmaceutical giant Johnson & Johnson’s (J&J) attempt to extend its monopoly on manufacturing the drug in India beyond July 2023.
J&J’s primary patents on Bedaquiline expire in July, paving ...